Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050889 | 0.77 | PKM (0.56) | PKMNPC1RAB9AMAPTNPSR1 | |
| SCHEMBL28398773 | 0.76 | CYP2C19 (0.43) | MAPTSMN1; SMN2CYP2C19CA2LMNA | |
| SCHEMBL1153683 | 0.73 | PKM (0.46) | PKMNPC1RAB9AMAPTNPSR1 | |
| SCHEMBL719388 | 0.70 | CYP2C19 (0.51) | PTGS2CYP2C9PTGS1PDPK1CYP2C19 | |
| SCHEMBL3382600 | 0.69 | PKM (0.57) | PKMNPC1RAB9AMAPTNPSR1 | |
| SCHEMBL21382084 | 0.68 | CYP2C19 (0.39) | NPSR1PTGS2CYP2C9PTGS1PDPK1 | |
| SCHEMBL8111889 | 0.68 | PKM (0.55) | PKMNPC1RAB9AMAPTNPSR1 | |
| SCHEMBL31033502 | 0.67 | CYP2C19 (0.47) | PKMRAB9AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL6549310 | 0.66 | CA2 (0.54) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL6937368 | 0.66 | CA2 (0.54) | MAPTCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| CN-101687796-B | Palladium-catalyzed coupling reaction of terminal alkynes with heteroaryltosylates and heteroarylbenzenesulfonates | SANOFI AVENTIS SPA | 2013-08-14 | — | — | CN | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687796-A | Palladium-catalyzed coupling reaction of terminal alkynes with heteroaryltosylates and heteroarylbenzenesulfonates | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | DDT, TYR, DDC | PKM 1822/4885NPC1 3809/4885RAB9A 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.